Vero Biotech Inc.
$4.4K 9 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Pajunk Medical Systems, LP
Pajunk Medical Systems, LP reported $4,413.10 across General Payments, Research, and Ownership to 95 physicians and teaching hospitals across 95 transactions.
- $4.4K Below-median payer
- All-tracks total
- 95 Below-median volume
- Transactions
- 95 Below-median reach
- Recipients
- −$14.4K
- General Payments vs PY2023
Pajunk Medical Systems, LP reported $4,413.10 across all CMS Open Payments tracks (General + Research + Ownership) to 95 physicians and teaching hospitals in Program Year 2024 - ranking #1726 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $4,413.10, averaging $46.45 per recipient.
Pajunk Medical Systems, LP's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer pajunk-medical-systems-lp Pajunk Medical Systems, LP
$4.4K · #1726/1,925 · 0.0% industry · PY2024
- TOT $4.4K
- RANK #1726
- SHARE 0.0%
- TXN 95
- RCP 95
- CAT 2
- GEN $4.4K
- ΔGEN −$14.4K
- TOP1 9.9%
- PY 2024
Volume peers
Nearest volume peer: Vero Biotech Inc. ($4.4K)
Pajunk Medical Systems, LP sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Pajunk Medical Systems, LP's CMS-reported General Payments decreased by $14.4K (−76.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PAJUNK MEDICAL SYSTEMS, LPPY2023: PAJUNK MEDICAL SYSTEMS, LPPY2024: Pajunk Medical Systems, LP. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $18,798.57
- PY2024
- $4,413.10
What the Data Shows for Pajunk Medical Systems, LP
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Pajunk Medical Systems, LP that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Food and Beverage" leads the 2-category general-payment breakdown below at $4.0K (90.1% of General Payments, 94 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Food and Beverage" leads Pajunk Medical Systems, LP's 2-category general-payment breakdown at $4.0K, 90.1% of the reported total.
How Pajunk Medical Systems, LP divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $4.0K | 94 | 90.1% |
| Consulting Fee | $437.50 | 1 | 9.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,962.94 (44.5%) of $4,413.10 in this company's General Payments records across 95 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Pajunk Medical Systems, LP
The five named recipients with the highest reported General Payments from this company
- 1
William Bullock
$437.50 across 1 reported transactions
- 2
Jerry Jones
$381.36 across 1 reported transactions
- 3
James Smyth
$381.36 across 1 reported transactions
- 4
Eugene Viscusi
$381.36 across 1 reported transactions
- 5
Eric Silverman
$381.36 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Pajunk Medical Systems, LP ranks #1726 of 1,925 by total payments (bottom 10% by spend) but is notably more concentrated than that alone would suggest -- #1,268 of 1,838 by HHI (bottom 31% least concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Novocure Inc. : $1.2M total payments, HHI 549
- Blue Surgical Llc : $12.0K total payments, HHI 549
- IBA Proton Therapy, Inc. : $24.6K total payments, HHI 548
- Rattan And Associates : $17.3K total payments, HHI 548
- Apellis Pharmaceuticals, Inc. : $3.5M total payments, HHI 546
- Abanza Inc. : $3.5K total payments, HHI 546
- Pajunk Medical Systems, LP (this company) : $4.4K total payments, HHI 538
- Cagent Vascular INC : $103.5K total payments, HHI 534
- ImmunoGen, Inc. : $95.7K total payments, HHI 533
- TELA Bio, Inc. : $2.1M total payments, HHI 531
- Medistim USA, Inc. : $4.8K total payments, HHI 530
- Catheter Precision Inc. : $1.3K total payments, HHI 525
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Pajunk Medical Systems, LP's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Pajunk Medical Systems, LP.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Pajunk Medical Systems, LP.
Showing 6 of 1,924 companies with CMS-reported payment data.
VivaQuant Inc, dba Rhythm Express
$4.5K 257 recipients
Compare payment profiles
Cosa Medical, Llc
$4.3K 46 recipients
Compare payment profiles
Ensemble Orthopedics, Inc
$4.3K 46 recipients
Compare payment profiles
Dornier MedTech America, Inc
$4.3K 38 recipients
Compare payment profiles
Ferring Sendirian Berhad
$4.3K 1 recipients
Compare payment profiles
Put this to use
Pajunk Medical Systems, LP ranks #1726 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Pajunk Medical Systems, LP. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.